Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biocryst Pharmaceuticals Inc (BCRX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Biocryst Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 882796.
Total stock buying since 2015: $7,740,854.
Total stock sales since 2015: $65,393,745.
Total stock option exercises since 2015: $10,878,107.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 70,000 | $595,840 | 70,000 | $291,200 |
| 2024 | 183,601 | $1,048,336 | 20,289 | $135,266 | 0 | $0 |
| 2023 | 0 | $0 | 123,866 | $1,231,391 | 146,055 | $670,647 |
| 2022 | 0 | $0 | 1,947,419 | $26,457,835 | 1,975,467 | $3,707,756 |
| 2021 | 42,758 | $531,444 | 551,370 | $7,759,815 | 672,622 | $2,749,445 |
| 2020 | 54,000 | $220,320 | 161,760 | $1,312,176 | 161,760 | $671,303 |
| 2019 | 200,000 | $310,060 | 88,250 | $730,789 | 112,624 | $384,398 |
| 2018 | 0 | $0 | 360,417 | $2,933,193 | 491,386 | $1,109,440 |
| 2017 | 0 | $0 | 134,810 | $737,359 | 114,705 | $424,512 |
| 2016 | 792,755 | $5,527,994 | 4,108,638 | $20,903,095 | 61,714 | $178,785 |
| 2015 | 10,000 | $102,700 | 195,066 | $2,596,986 | 237,382 | $690,621 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 70,000 | $595,840 | 70,000 | $291,200 |
| 2024-12 | 0 | $0 | 7,000 | $52,780 | 0 | $0 |
| 2024-06 | 0 | $0 | 13,289 | $82,486 | 0 | $0 |
| 2024-05 | 183,601 | $1,048,336 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 16,866 | $135,362 | 0 | $0 |
| 2023-04 | 0 | $0 | 7,000 | $58,029 | 0 | $0 |
| 2023-03 | 0 | $0 | 0 | $0 | 31,055 | $99,997 |
| 2023-02 | 0 | $0 | 100,000 | $1,038,000 | 100,000 | $545,000 |
| 2023-01 | 0 | $0 | 0 | $0 | 15,000 | $25,650 |
| 2022-12 | 0 | $0 | 1,530,865 | $19,819,015 | 1,530,865 | $2,173,825 |
| 2022-11 | 0 | $0 | 31,515 | $437,428 | 100,000 | $142,000 |
| 2022-04 | 0 | $0 | 12,600 | $178,319 | 5,000 | $16,600 |
| 2022-03 | 0 | $0 | 183,439 | $3,163,213 | 150,602 | $488,411 |
| 2022-02 | 0 | $0 | 5,000 | $92,500 | 5,000 | $16,600 |
| 2022-01 | 0 | $0 | 184,000 | $2,767,360 | 184,000 | $870,320 |
| 2021-12 | 0 | $0 | 30,100 | $367,220 | 62,000 | $293,260 |
| 2021-11 | 42,758 | $531,444 | 5,000 | $61,350 | 5,000 | $16,600 |
| 2021-10 | 0 | $0 | 105,000 | $1,617,000 | 105,000 | $340,515 |
| 2021-09 | 0 | $0 | 85,000 | $1,284,060 | 91,000 | $246,973 |
| 2021-07 | 0 | $0 | 5,000 | $78,450 | 5,000 | $13,150 |
| 2021-05 | 0 | $0 | 280,020 | $3,874,473 | 308,872 | $1,444,466 |
| 2021-03 | 0 | $0 | 0 | $0 | 4,500 | $15,794 |
| 2021-02 | 0 | $0 | 41,250 | $477,262 | 91,250 | $378,687 |
| 2020-12 | 0 | $0 | 161,760 | $1,312,176 | 161,760 | $671,303 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-13 | Heggie Theresa (Director) | Sale | 70,000 | 8.51 | 595,840 |
| 2025-08-13 | Heggie Theresa (Director) | Option Ex | 70,000 | 4.16 | 291,200 |
| 2024-12-13 | Hutson Nancy J (Director) | Sale | 7,000 | 7.54 | 52,780 |
| 2024-06-24 | Mckee Amy E (Director) | Sale | 8,600 | 6.32 | 54,352 |
| 2024-06-17 | Sanders Machelle (Director) | Sale | 4,689 | 6.00 | 28,134 |
| 2024-05-30 | Levin Alan G (Director) | Buy | 7,861 | 6.36 | 49,995 |
| 2024-05-24 | Aselage Steve (Director) | Buy | 2,500 | 6.40 | 16,000 |
| 2024-05-20 | Hutson Nancy J (Director) | Buy | 5,000 | 6.38 | 31,900 |
| 2024-05-20 | Milano Vincent (Director) | Buy | 15,000 | 6.25 | 93,750 |
| 2024-05-14 | Doyle Anthony (Chief Financial Officer) | Buy | 36,300 | 5.57 | 202,191 |
| 2024-05-14 | Thackray Helen M. (Chief R&D Officer) | Buy | 30,000 | 5.86 | 175,800 |
| 2024-05-13 | Gayer Charles K (Chief Commercial Officer) | Buy | 30,000 | 5.47 | 164,100 |
| 2024-05-13 | Barnes Alane P (Chief Legal Officer) | Buy | 5,000 | 5.53 | 27,650 |
| 2024-05-13 | Galson Steven K (Director) | Buy | 21,940 | 5.49 | 120,450 |
| 2024-05-13 | Stonehouse Jon P (President & CEO) | Buy | 30,000 | 5.55 | 166,500 |
| 2023-06-15 | Sanders Machelle (Director) | Sale | 4,000 | 7.98 | 31,920 |
| 2023-06-14 | Hutson Nancy J (Director) | Sale | 12,866 | 8.04 | 103,442 |
| 2023-04-03 | Thackray Helen M. (Chief R&D Officer) | Sale | 7,000 | 8.29 | 58,029 |
| 2023-03-21 | Stonehouse Jon P (President & CEO) | Option Ex | 31,055 | 3.22 | 99,997 |
| 2023-02-01 | Stonehouse Jon P (President & CEO) | Sale | 100,000 | 10.38 | 1,038,000 |
| 2023-02-01 | Stonehouse Jon P (President & CEO) | Option Ex | 100,000 | 5.45 | 545,000 |
| 2023-01-31 | Lee Kenneth B Jr (Director) | Option Ex | 15,000 | 1.71 | 25,650 |
| 2022-12-02 | Stonehouse Jon P (President & CEO) | Sale | 247,968 | 12.80 | 3,173,988 |
| 2022-12-02 | Stonehouse Jon P (President & CEO) | Option Ex | 247,968 | 1.42 | 352,113 |
| 2022-12-01 | Jones Michael L (Exec. Director, Finance - PAO) | Sale | 25,800 | 13.01 | 335,658 |
| 2022-12-01 | Jones Michael L (Exec. Director, Finance - PAO) | Option Ex | 25,800 | 1.42 | 36,636 |
| 2022-12-01 | Stonehouse Jon P (President & CEO) | Sale | 644,751 | 13.00 | 8,381,763 |
| 2022-12-01 | Stonehouse Jon P (President & CEO) | Option Ex | 644,751 | 1.42 | 915,546 |
| 2022-11-14 | Babu Yarlagadda S (Chief Discovery Officer) | Sale | 31,515 | 13.88 | 437,428 |
| 2022-11-14 | Babu Yarlagadda S (Chief Discovery Officer) | Option Ex | 100,000 | 1.42 | 142,000 |
| 2022-04-18 | Abercrombie George B (Director) | Sale | 5,000 | 11.04 | 55,199 |
| 2022-04-18 | Abercrombie George B (Director) | Option Ex | 5,000 | 3.32 | 16,600 |
| 2022-04-01 | Thackray Helen M. (Chief R&D Officer) | Sale | 7,600 | 16.20 | 123,120 |
| 2022-03-10 | Sheridan William P (Chief Medical Officer) | Sale | 161,139 | 17.25 | 2,780,453 |
| 2022-03-10 | Sheridan William P (Chief Medical Officer) | Option Ex | 148,302 | 3.22 | 477,532 |
| 2022-03-07 | Babu Yarlagadda S (Chief Discovery Officer) | Sale | 20,000 | 17.16 | 343,200 |
| 2022-03-01 | Jones Michael L (Exec. Director, Finance - PAO) | Sale | 2,300 | 17.20 | 39,560 |
| 2022-03-01 | Jones Michael L (Exec. Director, Finance - PAO) | Option Ex | 2,300 | 4.73 | 10,879 |
| 2022-02-15 | Abercrombie George B (Director) | Sale | 5,000 | 18.50 | 92,500 |
| 2022-02-15 | Abercrombie George B (Director) | Option Ex | 5,000 | 3.32 | 16,600 |
| 2022-01-11 | Stonehouse Jon P (President & CEO) | Sale | 184,000 | 15.04 | 2,767,360 |
| 2022-01-11 | Stonehouse Jon P (President & CEO) | Option Ex | 184,000 | 4.73 | 870,320 |
| 2021-12-07 | Babu Yarlagadda S (Chief Discovery Officer) | Sale | 30,100 | 12.20 | 367,220 |
| 2021-12-07 | Babu Yarlagadda S (Chief Discovery Officer) | Option Ex | 62,000 | 4.73 | 293,260 |
| 2021-11-24 | Milano Vincent | Buy | 7,500 | 12.19 | 91,425 |
| 2021-11-23 | Doyle Anthony (Chief Financial Officer) | Buy | 35,258 | 12.48 | 440,019 |
| 2021-11-15 | Abercrombie George B (Director) | Sale | 5,000 | 12.27 | 61,350 |
| 2021-11-15 | Abercrombie George B (Director) | Option Ex | 5,000 | 3.32 | 16,600 |
| 2021-10-15 | Hutson Nancy J (Director) | Sale | 105,000 | 15.40 | 1,617,000 |
| 2021-10-15 | Hutson Nancy J (Director) | Option Ex | 105,000 | 3.24 | 340,515 |
| 2021-09-15 | Abercrombie George B (Director) | Sale | 5,000 | 15.06 | 75,300 |
| 2021-09-15 | Abercrombie George B (Director) | Option Ex | 5,000 | 2.63 | 13,150 |
| 2021-09-13 | Lee Kenneth B Jr (Director) | Sale | 6,000 | 15.35 | 92,100 |
| 2021-09-13 | Lee Kenneth B Jr (Director) | Option Ex | 15,000 | 3.22 | 48,300 |
| 2021-09-10 | Abercrombie George B (Director) | Sale | 74,000 | 15.09 | 1,116,660 |
| 2021-09-10 | Abercrombie George B (Director) | Option Ex | 71,000 | 2.61 | 185,523 |
| 2021-07-15 | Abercrombie George B (Director) | Sale | 5,000 | 15.69 | 78,450 |
| 2021-07-15 | Abercrombie George B (Director) | Option Ex | 5,000 | 2.63 | 13,150 |
| 2021-05-28 | Sheridan William P (Chief Medical Officer) | Sale | 91,814 | 15.02 | 1,379,046 |
| 2021-05-28 | Sheridan William P (Chief Medical Officer) | Option Ex | 91,814 | 5.26 | 482,666 |
| 2021-05-27 | Sheridan William P (Chief Medical Officer) | Sale | 71,759 | 15.00 | 1,076,385 |
| 2021-05-27 | Sheridan William P (Chief Medical Officer) | Option Ex | 71,759 | 5.26 | 377,237 |
| 2021-05-24 | Abercrombie George B (Director) | Sale | 6,667 | 13.90 | 92,671 |
| 2021-05-24 | Abercrombie George B (Director) | Option Ex | 6,667 | 2.63 | 17,534 |
| 2021-05-12 | Barnes Alane P (Chief Legal Officer) | Option Ex | 35,852 | 4.73 | 169,579 |
| 2021-05-11 | Barnes Alane P (Chief Legal Officer) | Sale | 102,780 | 12.04 | 1,237,471 |
| 2021-05-11 | Barnes Alane P (Chief Legal Officer) | Option Ex | 102,780 | 3.87 | 397,450 |
| 2021-05-10 | Abercrombie George B (Director) | Sale | 7,000 | 12.70 | 88,900 |
| 2021-03-18 | Jones Michael L (Exec. Director, Finance - PAO) | Option Ex | 4,500 | 3.51 | 15,794 |
| 2021-02-22 | Sheridan William P (Senior VP - CMO) | Sale | 41,250 | 11.57 | 477,262 |
| 2021-02-22 | Sheridan William P (Senior VP - CMO) | Option Ex | 41,250 | 4.15 | 171,187 |
| 2021-02-19 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Option Ex | 50,000 | 4.15 | 207,500 |
| 2020-12-15 | Stonehouse Jon P (President & CEO) | Sale | 134,278 | 8.32 | 1,117,192 |
| 2020-12-15 | Stonehouse Jon P (President & CEO) | Option Ex | 134,278 | 4.15 | 557,253 |
| 2020-12-11 | Barnes Alane P (Senior VP, Chief Legal Officer) | Sale | 13,741 | 7.96 | 109,378 |
| 2020-12-11 | Barnes Alane P (Senior VP, Chief Legal Officer) | Option Ex | 13,741 | 4.15 | 57,025 |
| 2020-12-04 | Barnes Alane P (Senior VP, Chief Legal Officer) | Sale | 13,741 | 6.23 | 85,606 |
| 2020-12-04 | Barnes Alane P (Senior VP, Chief Legal Officer) | Option Ex | 13,741 | 4.15 | 57,025 |
| 2020-08-11 | Doyle Anthony (Chief Financial Officer) | Buy | 54,000 | 4.08 | 220,320 |
| 2019-11-18 | Sniecinski Megan (Chief Business Officer) | Buy | 45,000 | 1.45 | 65,250 |
| 2019-11-18 | Heggie Theresa (Director) | Buy | 5,000 | 1.45 | 7,250 |
| 2019-11-18 | Barnes Alane P (Senior VP, Chief Legal Officer) | Buy | 20,000 | 1.45 | 29,000 |
| 2019-11-18 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Buy | 25,000 | 1.45 | 36,250 |
| 2019-11-18 | Stonehouse Jon P (President & CEO) | Buy | 50,000 | 1.45 | 72,500 |
| 2019-11-18 | Hutson Nancy J (Director) | Buy | 10,000 | 1.45 | 14,500 |
| 2019-11-18 | Aselage Steve (Director) | Buy | 15,000 | 1.45 | 21,750 |
| 2019-11-18 | Ingram Robert Alexander (Director) | Buy | 20,000 | 1.45 | 29,000 |
| 2019-11-18 | Lee Kenneth B Jr (Director) | Buy | 5,000 | 1.45 | 7,250 |
| 2019-05-22 | Aselage Steve (Director) | Buy | 3,000 | 3.57 | 10,710 |
| 2019-05-17 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 2,500 | 7.45 | 18,625 |
| 2019-05-16 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 7,250 | 7.72 | 55,970 |
| 2019-05-16 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 4,750 | 1.42 | 6,745 |
| 2019-05-15 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 7,250 | 7.92 | 57,420 |
| 2019-05-15 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 4,750 | 1.42 | 6,745 |
| 2019-05-14 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 4,500 | 7.62 | 34,290 |
| 2019-05-14 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 4,500 | 1.42 | 6,390 |
| 2019-05-13 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 9,750 | 7.76 | 75,660 |
| 2019-05-13 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 9,750 | 5.51 | 53,722 |
| 2019-05-09 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 9,750 | 7.63 | 74,392 |
| 2019-05-09 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 9,750 | 5.51 | 53,722 |
| 2019-05-06 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 9,000 | 7.75 | 69,750 |
| 2019-05-06 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 9,000 | 5.51 | 49,590 |
| 2019-05-02 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 7,750 | 7.30 | 56,575 |
| 2019-05-02 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 7,750 | 5.51 | 42,702 |
| 2019-04-04 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 7,500 | 8.81 | 66,075 |
| 2019-04-04 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 7,500 | 5.51 | 41,325 |
| 2019-03-12 | Aselage Steve (Director) | Buy | 2,000 | 8.30 | 16,600 |
| 2019-01-31 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Option Ex | 31,874 | 1.20 | 38,248 |
| 2019-01-28 | Powell Lynne (Senior VP - CCO) | Sale | 6,000 | 9.89 | 59,370 |
| 2019-01-28 | Powell Lynne (Senior VP - CCO) | Option Ex | 6,000 | 3.22 | 19,320 |
| 2019-01-28 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 5,000 | 9.85 | 49,250 |
| 2019-01-28 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 5,000 | 5.45 | 27,250 |
| 2019-01-25 | Powell Lynne (Senior VP - CCO) | Sale | 6,000 | 9.60 | 57,600 |
| 2019-01-25 | Powell Lynne (Senior VP - CCO) | Option Ex | 6,000 | 3.22 | 19,320 |
| 2019-01-18 | Powell Lynne (Senior VP - CCO) | Sale | 2,000 | 9.40 | 18,800 |
| 2019-01-18 | Powell Lynne (Senior VP - CCO) | Option Ex | 2,000 | 3.22 | 6,440 |
| 2019-01-16 | Powell Lynne (Senior VP - CCO) | Sale | 3,046 | 9.27 | 28,236 |
| 2019-01-16 | Powell Lynne (Senior VP - CCO) | Option Ex | 3,046 | 3.22 | 9,808 |
| 2019-01-14 | Powell Lynne (Senior VP - CCO) | Sale | 954 | 9.20 | 8,776 |
| 2019-01-14 | Powell Lynne (Senior VP - CCO) | Option Ex | 954 | 3.22 | 3,071 |
| 2018-12-18 | Sheridan William P (Senior VP - CMO) | Sale | 20,488 | 7.58 | 155,299 |
| 2018-12-10 | Powell Lynne (Senior VP - CCO) | Sale | 4,000 | 9.06 | 36,240 |
| 2018-12-10 | Powell Lynne (Senior VP - CCO) | Option Ex | 4,000 | 3.22 | 12,880 |
| 2018-12-04 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,922 | 9.45 | 37,062 |
| 2018-12-03 | Stonehouse Jon P (President & CEO) | Sale | 80,000 | 9.12 | 729,599 |
| 2018-12-03 | Stonehouse Jon P (President & CEO) | Option Ex | 80,000 | 1.20 | 96,000 |
| 2018-11-30 | Barnes Alane P (Senior VP, Chief Legal Officer) | Sale | 44,290 | 9.07 | 401,710 |
| 2018-11-30 | Barnes Alane P (Senior VP, Chief Legal Officer) | Option Ex | 25,000 | 1.42 | 35,500 |
| 2018-11-28 | Erck Stanley C (Director) | Option Ex | 8,333 | 1.49 | 12,416 |
| 2018-11-23 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,500 | 9.66 | 33,810 |
| 2018-11-23 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,500 | 3.78 | 13,230 |
| 2018-11-21 | Powell Lynne (Senior VP - CCO) | Sale | 14,455 | 9.04 | 130,600 |
| 2018-11-21 | Powell Lynne (Senior VP - CCO) | Option Ex | 12,000 | 3.22 | 38,640 |
| 2018-11-21 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 12,000 | 9.24 | 110,939 |
| 2018-11-21 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 12,000 | 4.62 | 55,380 |
| 2018-11-20 | Powell Lynne (Senior VP - CCO) | Sale | 15,277 | 8.56 | 130,847 |
| 2018-11-20 | Powell Lynne (Senior VP - CCO) | Option Ex | 9,127 | 3.22 | 29,388 |
| 2018-11-20 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 11,123 | 8.66 | 96,325 |
| 2018-11-20 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 11,123 | 3.50 | 38,930 |
| 2018-11-19 | Powell Lynne (Senior VP - CCO) | Sale | 193 | 8.30 | 1,601 |
| 2018-11-19 | Powell Lynne (Senior VP - CCO) | Option Ex | 193 | 3.22 | 621 |
| 2018-11-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 75 | 8.30 | 622 |
| 2018-11-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 75 | 3.78 | 283 |
| 2018-11-08 | Powell Lynne (Senior VP - CCO) | Sale | 5,280 | 8.15 | 43,032 |
| 2018-11-08 | Powell Lynne (Senior VP - CCO) | Option Ex | 5,280 | 3.22 | 17,001 |
| 2018-11-08 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 13,415 | 8.20 | 109,935 |
| 2018-11-08 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 13,415 | 3.50 | 46,952 |
| 2018-11-07 | Powell Lynne (Senior VP - CCO) | Sale | 300 | 8.00 | 2,400 |
| 2018-11-07 | Powell Lynne (Senior VP - CCO) | Option Ex | 300 | 3.22 | 966 |
| 2018-11-07 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 672 | 8.00 | 5,376 |
| 2018-11-07 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 672 | 3.22 | 2,163 |
| 2018-11-05 | Powell Lynne (Senior VP - CCO) | Sale | 100 | 8.00 | 800 |
| 2018-11-05 | Powell Lynne (Senior VP - CCO) | Option Ex | 100 | 3.22 | 322 |
| 2018-11-05 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 215 | 8.00 | 1,720 |
| 2018-11-05 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 215 | 3.22 | 692 |
| 2018-11-02 | Powell Lynne (Senior VP - CCO) | Sale | 1,000 | 8.00 | 8,000 |
| 2018-11-02 | Powell Lynne (Senior VP - CCO) | Option Ex | 1,000 | 3.22 | 3,220 |
| 2018-11-02 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 10,856 | 7.87 | 85,436 |
| 2018-11-02 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 10,856 | 3.50 | 37,996 |
| 2018-11-01 | Powell Lynne (Senior VP - CCO) | Sale | 1,544 | 7.51 | 11,595 |
| 2018-10-19 | Powell Lynne (Senior VP - CCO) | Sale | 100 | 7.50 | 750 |
| 2018-10-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,150 | 7.45 | 23,467 |
| 2018-10-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,150 | 3.78 | 11,907 |
| 2018-10-03 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 1,072 | 7.36 | 7,884 |
| 2018-10-03 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 1,072 | 3.50 | 3,752 |
| 2018-10-02 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 8,778 | 7.23 | 63,464 |
| 2018-10-02 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 8,778 | 3.50 | 30,723 |
| 2018-08-09 | Sheridan William P (Senior VP - CMO) | Sale | 62,500 | 7.03 | 439,375 |
| 2018-08-09 | Sheridan William P (Senior VP - CMO) | Option Ex | 62,500 | 1.42 | 88,750 |
| 2018-06-01 | Sheridan William P (Senior VP - CMO) | Sale | 42,112 | 6.30 | 265,305 |
| 2018-06-01 | Sheridan William P (Senior VP - CMO) | Option Ex | 42,112 | 2.58 | 108,648 |
| 2018-05-17 | Stonehouse Jon P (President & CEO) | Option Ex | 70,427 | 1.42 | 100,006 |
| 2018-05-15 | Barnes Alane P (VP, General Counsel & Corp Sec) | Option Ex | 12,500 | 1.42 | 17,750 |
| 2018-03-06 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Option Ex | 30,000 | 3.26 | 97,800 |
| 2018-02-28 | Barnes Alane P (VP, General Counsel & Corp Sec) | Option Ex | 6,709 | 3.26 | 21,871 |
| 2018-02-28 | Stonehouse Jon P (President & CEO) | Option Ex | 56,949 | 3.26 | 185,653 |
| 2017-11-13 | Sheridan William P (Senior VP - CMO) | Sale | 64,310 | 4.72 | 303,543 |
| 2017-09-18 | Cohen Fred E (Director) | Sale | 54,250 | 5.42 | 294,035 |
| 2017-09-18 | Cohen Fred E (Director) | Option Ex | 54,250 | 4.27 | 231,647 |
| 2017-05-22 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 7,750 | 4.73 | 36,657 |
| 2017-03-20 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,250 | 9.20 | 29,899 |
| 2017-03-20 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,250 | 3.78 | 12,285 |
| 2017-03-16 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 36,455 | 2.60 | 94,783 |
| 2017-03-10 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,250 | 9.06 | 29,445 |
| 2017-03-10 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,250 | 3.78 | 12,285 |
| 2017-03-08 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 6,500 | 8.43 | 54,762 |
| 2017-03-08 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 6,500 | 3.78 | 24,570 |
| 2017-03-06 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,250 | 7.90 | 25,675 |
| 2017-03-06 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,250 | 3.78 | 12,285 |
| 2016-12-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,250 | 7.45 | 24,212 |
| 2016-12-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,250 | 3.78 | 12,285 |
| 2016-09-14 | Barnes Alane P (VP, General Counsel & Corp Sec) | Sale | 8,357 | 4.27 | 35,684 |
| 2016-08-25 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Sale | 30,000 | 4.06 | 121,799 |
| 2016-08-16 | Baker Felix (10% Owner) | Sale | 990 | 4.29 | 4,246 |
| 2016-08-15 | Baker Felix (10% Owner) | Sale | 400,000 | 4.83 | 1,931,200 |
| 2016-08-12 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 4,558 | 5.22 | 23,792 |
| 2016-08-12 | Baker Felix (10% Owner) | Sale | 3,645,600 | 5.13 | 18,690,991 |
| 2016-08-11 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 1,306 | 5.05 | 6,595 |
| 2016-08-09 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 14,577 | 4.43 | 64,576 |
| 2016-02-05 | Baker Felix (10% Owner) | Buy | 45,000 | 6.33 | 284,670 |
| 2016-02-04 | Baker Felix (10% Owner) | Buy | 24,800 | 6.65 | 164,920 |
| 2016-02-03 | Baker Felix (10% Owner) | Buy | 91,187 | 6.29 | 573,292 |
| 2016-02-02 | Baker Felix (10% Owner) | Buy | 91,728 | 6.52 | 598,341 |
| 2016-01-29 | Barnes Alane P (VP, General Counsel & Corp Sec) | Option Ex | 19,368 | 1.42 | 27,502 |
| 2016-01-28 | Baker Felix (10% Owner) | Buy | 25,000 | 6.88 | 172,025 |
| 2016-01-27 | Baker Felix (10% Owner) | Buy | 63,345 | 6.98 | 441,958 |
| 2016-01-22 | Baker Felix (10% Owner) | Buy | 3,200 | 7.00 | 22,390 |
| 2016-01-21 | Baker Felix (10% Owner) | Buy | 103,600 | 7.29 | 755,347 |
| 2016-01-20 | Stonehouse Jon P (President & CEO) | Option Ex | 24,096 | 4.15 | 99,998 |
| 2016-01-20 | Baker Felix (10% Owner) | Buy | 52,695 | 6.91 | 363,911 |
| 2016-01-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 15,000 | 2.60 | 39,000 |
| 2016-01-19 | Baker Felix (10% Owner) | Buy | 92,200 | 7.12 | 656,740 |
| 2016-01-15 | Baker Felix (10% Owner) | Buy | 200,000 | 7.47 | 1,494,400 |
| 2015-12-21 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,052 | 10.86 | 33,144 |
| 2015-12-17 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,000 | 10.49 | 31,470 |
| 2015-07-20 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,500 | 16.50 | 57,750 |
| 2015-07-15 | Stonehouse Jon P (President & CEO) | Option Ex | 33,868 | 11.81 | 399,981 |
| 2015-06-22 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,750 | 16.00 | 60,000 |
| 2015-06-22 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,750 | 4.73 | 17,737 |
| 2015-06-19 | Barnes Alane P (VP, General Counsel & Corp Sec) | Sale | 3,000 | 15.00 | 45,000 |
| 2015-06-19 | Sheridan William P (Senior VP - CMO) | Sale | 70,389 | 15.05 | 1,059,354 |
| 2015-06-19 | Sheridan William P (Senior VP - CMO) | Option Ex | 70,389 | 1.20 | 84,466 |
| 2015-06-19 | Stonehouse Jon P (President & CEO) | Sale | 20,000 | 15.02 | 300,400 |
| 2015-06-19 | Stonehouse Jon P (President & CEO) | Option Ex | 20,000 | 1.20 | 24,000 |
| 2015-06-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 6,675 | 15.00 | 100,125 |
| 2015-06-19 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 3,175 | 3.78 | 12,001 |
| 2015-06-18 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 9,700 | 13.92 | 134,994 |
| 2015-06-18 | Staab Thomas R Ii (Senior Vice President and CFO) | Option Ex | 6,200 | 3.78 | 23,436 |
| 2015-06-05 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 6,000 | 12.75 | 76,500 |
| 2015-06-01 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,000 | 12.00 | 36,000 |
| 2015-05-18 | Staab Thomas R Ii (Senior Vice President and CFO) | Sale | 3,000 | 11.00 | 33,000 |
| 2015-03-19 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Sale | 12,105 | 10.16 | 122,986 |
| 2015-03-05 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Sale | 37,400 | 10.59 | 396,066 |
| 2015-03-04 | Babu Yarlagadda S (Senior VP - Drug Discovery) | Sale | 10,495 | 10.50 | 110,197 |
| 2015-02-20 | Hutson Nancy J (Director) | Buy | 10,000 | 10.27 | 102,700 |
| 2015-01-08 | Cohen Fred E (Director) | Option Ex | 100,000 | 1.29 | 129,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of BCRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Biocryst Pharmaceuticals Inc (symbol BCRX, CIK number 882796) see the Securities and Exchange Commission (SEC) website.